Vol. 17/No. 3 | OncologyLive

Demetri's Team Approach Translates Into Success in Sarcoma Research

February 10, 2016

George D. Demetri, MD, whose teamwork approach has helped pave the way for new drugs for hard-to-treat sarcomas, was honored in the Gastrointestinal Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Durvalumab/Tremelimumab Combo Explored in Lung Cancer Trial

February 05, 2016

With the approval of a dual checkpoint blockade treatment in melanoma, researchers hope to have similar success in a phase III trial that combines a PD-L1 inhibitor and CTLA-4 antibody in patients with non–small cell lung cancer.

Scientific Misconduct in Oncology: A Distasteful Subject That Requires Acknowledgment and Attention

February 05, 2016

The greatest concern with the profoundly distressing episode that has unfolded at Duke University in recent years is whether it will truly serve as a learning experience that would help prevent future misconduct— events that have the potential to result in serious harm to highly vulnerable patients with cancer.

Timing Is Everything

February 02, 2016

As anticancer therapies continue to improve outcomes for patients, questions about how best to deploy these new options abound. In this issue of OncologyLive, we explore two of the pressing questions that have arisen in treating patients with hematologic malignancies.

EGFR Inhibitors Continue March in Mutated NSCLC

January 29, 2016

After a rocky start, drugs that inhibit the epidermal growth factor receptor pathway have evolved into a new treatment paradigm for patients with non–small cell lung cancer whose tumors harbor EGFR mutations.

Experts Emphasize Importance of Preventing Progression in CML

January 29, 2016

Early diagnosis and early commencement of the most effective treatment available are essential in managing patients with chronic myeloid leukemia, particularly since therapeutic options have expanded and testing technology has advanced.

Getting to Zero: MRD Yardstick for Myeloma Inches Closer

January 29, 2016

Researchers and oncologists are excited about the prospect of MRD becoming equally useful in the assessment and management of patients with multiple myeloma, particularly in light of the development of new, more effective therapies and the current limited ability to assess their effectiveness.